Trend analysis as per recent USFDA guideline [Bioanalytics]

posted by dshah  – India/United Kingdom, 2020-08-01 09:32 (1363 d 11:29 ago) – Posting: # 21815
Views: 5,809

Dear All!

If we consider the recent FDA guideline or ICH M10, i believe trend analysis for IS response, CC and QCs is also required. FDA does ask if there is upward or downward trend observed. The important point for SOP of CRO should be - allowed limit for IS response. If this not limited for that 3 subjects, then i believe CRO's practice and SOP needs to be revised.

Regards,
Dshah


Edit: Guidelines linked. [Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
22,993 posts in 4,828 threads, 1,652 registered users;
127 visitors (0 registered, 127 guests [including 6 identified bots]).
Forum time: 21:01 CEST (Europe/Vienna)

Never never never never use Excel.
Not even for calculation of arithmetic means.    Martin Wolfsegger

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5